<SEC-DOCUMENT>0001193125-24-215939.txt : 20240909
<SEC-HEADER>0001193125-24-215939.hdr.sgml : 20240909
<ACCEPTANCE-DATETIME>20240909163300
ACCESSION NUMBER:		0001193125-24-215939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240909
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20240909
DATE AS OF CHANGE:		20240909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		241287647

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d881331d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ions="http://ionispharma.com/20240909" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2024-09-09_to_2024-09-09" name="dei:AmendmentFlag" contextRef="duration_2024-09-09_to_2024-09-09">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2024-09-09_to_2024-09-09" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-09_to_2024-09-09">0000874015</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ions-20240909.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-09_to_2024-09-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-09</xbrli:startDate> <xbrli:endDate>2024-09-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_1">8-K</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-09_to_2024-09-09" format="ixt:date-monthname-day-year-en" id="Fact_0">September&#160;9, 2024</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityRegistrantName" id="ixv-579">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-580">Delaware</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction of Incorporation)</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityFileNumber" id="ixv-581">000-19125</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityTaxIdentificationNumber" id="ixv-582">33-0336973</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityAddressAddressLine1" id="ixv-583">2855 Gazelle Court</ix:nonNumeric></p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_2">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_4"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_5">CA</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_3">92010</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices and Zip Code)</p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:CityAreaCode" id="ixv-588">760</ix:nonNumeric>) <ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:LocalPhoneNumber" id="ixv-589">931-9200</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="ixv-590">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="ixv-591">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="ixv-592">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="ixv-593">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_15">Common Stock, $.001 Par Value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top">&#8220;<ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:TradingSymbol" id="ixv-595">IONS</ix:nonNumeric>&#8221;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-596">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (Section <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric contextRef="duration_2024-09-09_to_2024-09-09" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-597">&#9744;</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p><p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;9, 2024, Ionis Pharmaceuticals, Inc. (or Ionis, we, us or our company) filed a preliminary prospectus supplement with the U.S. Securities and Exchange Commission, or the SEC, under its effective shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration Statement <span style="white-space:nowrap">No.&#160;333-275741),</span> or the Preliminary Prospectus Supplement, in connection with a proposed registered underwritten public offering of common stock.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preliminary Prospectus Supplement contains information relating to recent developments concerning Ionis&#8217; business and includes the following disclosure:</p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview</p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For three decades as a pioneer in <span style="white-space:nowrap">RNA-targeted</span> medicines, we have focused on bringing better futures to people with serious diseases. Today, we continue to drive innovation in RNA therapies. A deep understanding of disease biology and an industry-leading drug discovery technology propels our work, coupled with a passion and urgency to deliver better futures for patients.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have five marketed medicines to treat serious diseases: SPINRAZA (nusinersen), QALSODY (tofersen), WAINUA (eplontersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). We also have a rich innovative late- and <span style="white-space:nowrap">mid-stage</span> pipeline in neurology, cardiology and other areas of high patient need. We currently have nine medicines in Phase 3 development and multiple additional medicines in early and <span style="white-space:nowrap">mid-stage</span> development.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our multiple sources of revenue and our capital structure to continue investing in our commercial readiness efforts for multiple late-stage programs, our innovative pipeline and our technology. By continuing to focus on these priorities, we believe we are well positioned to drive future growth and to bring next-level value to patients and shareholders.</p><p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Marketed Medicines </span></p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Our partner, Biogen, is responsible for commercializing SPINRAZA worldwide. From inception through June 30, 2024, we have earned more than $2.2&#160;billion in revenues from our SPINRAZA collaboration, including more than $1.7&#160;billion in royalties on sales of SPINRAZA.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">QALSODY is an antisense medicine that received accelerated approval from the United States, or U.S., Food and Drug Administration, or FDA, in April 2023 and marketing authorization under exceptional circumstances from the European Medicines Agency, or EMA, in May 2024 for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis, or <span style="white-space:nowrap">SOD1-ALS,</span> a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. Our partner, Biogen, is responsible for commercializing QALSODY worldwide.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WAINUA is a once monthly, self-administered subcutaneous LIgand-Conjugated Antisense, or LICA, medicine that received approval from the FDA in December 2023 and Health Canada in June 2024 for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or <span style="white-space:nowrap">ATTRv-PN,</span> a debilitating, progressive, and fatal disease. WAINUA is the only approved medicine for the treatment of <span style="white-space:nowrap">ATTRv-PN</span> that can be self-administered via an auto-injector. We and AstraZeneca are commercializing WAINUA in the U.S. with the launch having commenced in January 2024. We and AstraZeneca are seeking regulatory approval for WAINUA in Europe and other parts of the world. We anticipate a regulatory decision from the EMA for WAINUA for the treatment of <span style="white-space:nowrap">ATTRv-PN</span> in the second half of 2024. We also anticipate additional regulatory approvals outside the U.S. in 2024. AstraZeneca has exclusive rights to commercialize WAINUA outside of the U.S.</p><p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TEGSEDI is a once weekly, self-administered subcutaneous medicine approved in the U.S., Europe, Canada and Brazil for the treatment of patients with <span style="white-space:nowrap">ATTRv-PN.</span> We sell TEGSEDI in the U.S. and Canada (collectively, North America) and Europe through our distribution agreement with Swedish Orphan Biovitrum AB, or Sobi. In October 2023, our agreement for TEGSEDI in North America was terminated. As a result, Sobi is transitioning responsibilities to us. In February 2024, we began the process to withdraw the TEGSEDI New Drug Application, or NDA. In Latin America, PTC Therapeutics International Limited, or PTC, is commercializing TEGSEDI in Brazil and is pursuing access in additional Latin American countries through its exclusive license agreement with us.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WAYLIVRA is a once weekly, self-administered, subcutaneous medicine approved in Europe and Brazil as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome, or FCS, and at high risk for pancreatitis. We sell WAYLIVRA in Europe through our distribution agreement with Sobi. In Latin America, PTC is commercializing WAYLIVRA in Brazil for two indications, FCS and familial partial lipodystrophy, or FPL, and is pursuing access in additional Latin American countries through its exclusive license agreement with us.</p><p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Medicines in Registration and Phase 3 Studies </span></p><p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We currently have nine medicines in registration or Phase 3 studies for eleven indications, which are:</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WAINUA is our medicine to treat patients with transthyretin amyloidosis, or ATTR, that is approved in the U.S. and Canada for the treatment of adults with <span style="white-space:nowrap">ATTRv-PN,</span> under regulatory review in other countries for <span style="white-space:nowrap">ATTRv-PN</span> and in development for ATTR cardiomyopathy, or <span style="white-space:nowrap">ATTR-CM.</span> In January 2024, we launched WAINUA for the treatment of adults with <span style="white-space:nowrap">ATTRv-PN</span> in the U.S. In September 2023, The Journal of the American Medical Association, or JAMA, published positive results from the Phase 3 NEURO-TTRansform study in patients with <span style="white-space:nowrap">ATTRv-PN</span> showing WAINUA halted disease progression and continuously improved quality of life at the <span style="white-space:nowrap">35-,</span> 66- and <span style="white-space:nowrap">85-week</span> analyses. In July 2023, we completed enrollment of the Phase 3 CARDIO-TTRansform study of WAINUA in patients with <span style="white-space:nowrap">ATTR-CM</span> with data expected in 2026. In February 2024, the FDA granted Fast Track designation to WAINUA for the treatment of patients with <span style="white-space:nowrap">ATTR-CM.</span> Additionally, in January 2022 and October 2023, the FDA and EMA, respectively, granted Orphan Drug designation to WAINUA for the treatment of ATTR.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Olezarsen is our medicine in development for FCS, an ultra-rare indication, and severe hypertriglyceridemia, or sHTG, a much broader indication. In June 2024, the FDA accepted our NDA for patients with FCS for Priority Review with a Prescription Drug User Fee Act, or PDUFA, date of December&#160;19, 2024. We expect to launch olezarsen in the U.S. for the treatment of FCS by the end of 2024. Additionally, we are currently preparing to submit an application in 2024 for regulatory approval for FCS in Europe. In April 2024, we opened our Expanded Access Program for patients with FCS in the U.S. Additionally, in April 2024, we presented positive Phase 3 Balance study data in patients with FCS and the Phase 2b Bridge study in patients with HTG and sHTG at the American College of Cardiology, or ACC, annual meeting with a simultaneous publication in the <span style="font-style:italic">New England Journal of Medicine</span>, or <span style="font-style:italic">NEJM</span>. In the Balance study, Olezarsen demonstrated substantial reductions in <span style="white-space:nowrap">apoC-III,</span> TGs, marked acute pancreatitis reductions, substantial reduction in hospitalizations and favorable safety and tolerability. Additionally, we are currently conducting a broad Phase 3 development program for olezarsen for the treatment of sHTG, including three Phase 3 studies supporting development (CORE, CORE2 and ESSENCE), which achieved full enrollment in 2024 and for which we expect data in 2025. The FDA granted Breakthrough Therapy designation, Orphan Drug designation and Fast Track designation to olezarsen for the treatment of FCS.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Donidalorsen is our medicine in development for hereditary angioedema, or HAE. In May 2024, we presented positive data from the Phase 3&#160;OASIS-HAE study in patients treated every four weeks and every eight weeks at the European Academy of Allergy and Clinical Immunology 2024 Congress. In addition, we presented positive data from OASISplus, our trial that includes an open-label, or OLE, cohort for patients rolling over from the Phase 3 study and a separate cohort for patients who have transitioned to donidalorsen from other prophylactic HAE medications that we refer to as the &#8220;switch study,&#8221; with simultaneous publications in <span style="font-style:italic">NEJM</span>. In December 2023 and June 2024, we licensed commercialization rights for donidalorsen to Otsuka Pharmaceutical Co., Ltd., or Otsuka, in Europe and the Asia-Pacific region, respectively. Throughout 2022 and 2023, we reported positive data from the Phase 2 study and Phase 2 OLE study, including <span style="white-space:nowrap">two-year</span> OLE data. We submitted the NDA to the FDA in August 2024. Otsuka is preparing to submit a Marketing Authorization Application, or MAA, to the EMA, which we anticipate to occur in 2024. We anticipate the launch of donidalorsen in the U.S. for the treatment of HAE in 2025. In September 2023 and February 2024, the FDA and EMA, respectively, granted Orphan Drug designation to donidalorsen.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zilganersen is our medicine in development for Alexander disease, or AxD. In July 2024, we completed enrollment in the Phase 3 portion of the ongoing study for patients with AxD. We anticipate data from this study in 2025. In September 2020 and October 2019, the FDA and EMA, respectively, granted Orphan Drug designation to zilganersen. Additionally in August 2020, the FDA granted rare pediatric designation to zilganersen.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ulefnersen is our medicine in development for amyotrophic lateral sclerosis, or ALS, with mutations in the fused in sarcoma gene, or FUS. We are currently conducting a Phase 3 study of ulefnersen in juvenile and adult patients with <span style="white-space:nowrap">FUS-ALS</span> for which we anticipate data in 2026. In August 2023 and September 2023, the FDA and EMA, respectively, granted Orphan Drug designation to ulefnersen.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">QALSODY is our marketed medicine to treat patients with <span style="white-space:nowrap">SOD1-ALS.</span> In April 2023, the FDA granted Biogen accelerated approval and in May 2024, the EMA granted Biogen marketing authorization under exceptional circumstances of QALSODY for patients with <span style="white-space:nowrap">SOD1-ALS.</span> Additionally, Biogen is evaluating QALSODY as a potential treatment for presymptomatic <span style="white-space:nowrap">SOD1-ALS</span> patients in the ongoing ATLAS study for which we anticipate data in 2028. In September 2016 and August 2016, the FDA and EMA, respectively, granted Orphan Drug designation to QALSODY.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pelacarsen is our medicine in development to treat patients with elevated lipoprotein(a)-driven cardiovascular disease. Novartis is developing pelacarsen, including conducting the ongoing Lp(a) HORIZON Phase 3 cardiovascular outcome study in patients with elevated Lp(a)-driven cardiovascular disease, which achieved full enrollment in July 2022 with more than 8,000 patients and for which we anticipate data in 2025. In April 2020, the FDA granted Fast Track designation to pelacarsen. Our partner, Novartis, has stated they anticipate submitting for regulatory approval in 2025, assuming the data are supportive.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bepirovirsen is our medicine in development for chronic hepatitis B virus, or HBV. GSK is developing bepirovirsen, including conducting the ongoing <span style="white-space:nowrap">B-Well</span> Phase 3 program in patients with HBV, which achieved full enrollment in June 2024 and for which we anticipate data in 2026. GSK reported positive results from Phase 2 studies in 2023, including durable response data from the Phase 2 <span style="white-space:nowrap">B-Sure</span> long-term <span style="white-space:nowrap">follow-up</span> study of bepirovirsen in complete responder patients from the Phase 2b <span style="white-space:nowrap">B-Clear</span> study of patients with HBV. In February 2024, the FDA granted Fast Track designation to bepirovirsen for the treatment of patients with HBV.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">IONIS-FB-L</span></span><sub style="font-size:75%; vertical-align:bottom">Rx</sub> is our medicine in development for immunoglobulin A, or IgA, nephropathy, or IgAN. In the second quarter of 2023, Roche advanced <span style="white-space:nowrap"><span style="white-space:nowrap">IONIS-FB-L</span></span><sub style="font-size:75%; vertical-align:bottom">Rx</sub> into Phase 3 development in patients with IgAN. In October 2023, we reported positive interim data from the ongoing Phase 2 study of <span style="white-space:nowrap"><span style="white-space:nowrap">IONIS-FB-L</span></span><sub style="font-size:75%; vertical-align:bottom">Rx</sub> in patients with IgAN.</p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Upcoming U.S. Approvals for Certain Drugs in Ionis&#8217; Pipeline<sup style="font-size:75%; vertical-align:top">1</sup></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; font-size:8pt; font-family:Times New Roman;font-weight:bold">Drug (target)/Indication</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">2024-2025</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">2026-2027</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2028+</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Olezarsen</span> (APOCIII)/<span style="font-style:italic">FCS</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Donidalorsen</span> (PKK)/<span style="font-style:italic">HAE</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WAINUA</span> (TTR)/<span style="font-style:italic">ATTR Cardiomyopathy</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Olezarsen</span> (APOCIII)/<span style="font-style:italic">sHTG</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Pelacarsen</span>/<span style="font-style:italic">Lp(a) CVD</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Bepirovirsen</span> (HBV)/<span style="font-style:italic">HBV Infection</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Zilganersen</span> (GFAP)/<span style="font-style:italic">Alexander Disease</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Ulefnersen</span> (FUS)/<span style="font-style:italic"><span style="white-space:nowrap">FUS-ALS</span></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">IONIS-FB-L</span></span><sub style="font-size:75%; vertical-align:bottom">Rx</sub></span> (Factor B)/<span style="font-style:italic">IgA Nephropathy</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Sapablursen</span> (TMPRSS6)/<span style="font-style:italic">Polycythemia Vera</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Next Wave Neurology Medicines</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">ION582</span> (UBE3A)/<span style="font-style:italic">Angelman syndrome</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap">&#10003;</td></tr> </table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">(1)</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any potential U.S. regulatory approval and related estimated timing are based on current assumptions and subject to risks and change.</p></td></tr> </table><p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent <span style="white-space:nowrap">Mid-Stage</span> Pipeline Developments</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ION582 - Angelman&#8217;s Syndrome</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reported positive data from the Phase 2 portion of the Phase 1/2a HALOS study of ION582 (UBE3A) in patients with Angelman syndrome at the Angelman Syndrome Foundation meeting in July 2024, including:</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Consistent improvements in key areas of clinical function, including communication, cognition and motor function,</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Evidence of consistent improvements across age groups and genotypes, and</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A favorable safety and tolerability profile.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expect to meet with the FDA for an end of Phase 2 meeting in the second half of 2024.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Anticipate initiating Phase 3 development of ION582 in the first half of 2025.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Presented positive Phase 2 data of ION224 (DGAT2) in patients with metabolic dysfunction-associated steatohepatitis.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Initiated the Phase 1b Orbit study of ION356 (PLP1) in patients with <span style="white-space:nowrap">Pelizaeus-Merzbacher</span> disease.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expect ION440 (MECP2) and an undisclosed genetic dementia target to enter clinical development in 2024.</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Discontinued development of <span style="white-space:nowrap"><span style="white-space:nowrap">IONIS-FB-L</span></span><sub style="font-size:75%; vertical-align:bottom">Rx</sub> for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) following completion of Phase 2 studies showing favorable safety profiles and good target engagement, but insufficient efficacy to advance into Phase 3 development.</p></td></tr> </table><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Other Medicines for High Patient Need in Development</p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sapablursen is our medicine in development for polycythemia vera, or PV. In December 2021, we initiated a Phase 2 study evaluating sapablursen in patients with phlebotomy dependent PV. In January 2024, the FDA granted Fast Track designation to sapablursen for PV.</p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements</p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding Ionis&#8217; expectations with respect to Ionis&#8217; business and the therapeutic and commercial potential of Ionis&#8217; marketed medicines, including SPINRAZA (nusinersen), QALSODY (tofersen), WAINUA (eplontersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen), as well as Ionis&#8217; additional medicines in development and technologies, the achievement of potential regulatory approvals for our medicines in development and the anticipated timing of any such approvals. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, Ionis claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Ionis&#8217; expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, macroeconomic and geopolitical events, Ionis&#8217; commercial products and the medicines in Ionis&#8217; pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Additional factors that could cause actual results to differ materially from those stated or implied by Ionis&#8217; forward-looking statements are disclosed in</p><p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Ionis&#8217; filings with the SEC, including in the section captioned &#8220;Risk Factors&#8221; in Ionis&#8217; most recent Annual Report on Form <span style="white-space:nowrap">10-K</span> and subsequently filed Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> and the Preliminary Prospectus Supplement. These forward-looking statements represent Ionis&#8217; judgment as of the time of this report. Ionis disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:45%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>
<td style="vertical-align:bottom"/>
<td style="width:3%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ONIS</small> P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">HARMACEUTICALS</small>, I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">NC</small>.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: September&#160;9, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Patrick R. O&#8217;Neil</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ATRICK</small> R. O&#8217;N<small style="font-weight:inherit;font-style:unset;text-decoration:unset">EIL</small></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, Chief Legal Officer and General<br/>Counsel</td></tr></table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&#160;</p></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>ions-20240909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 73.0.6 -->
<!-- Creation date: 9/9/2024 1:14:04 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:ions="http://ionispharma.com/20240909"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://ionispharma.com/20240909"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ions-20240909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ions-20240909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>ions-20240909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 73.0.6 -->
<!-- Creation date: 9/9/2024 1:14:04 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>ions-20240909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 73.0.6 -->
<!-- Creation date: 9/9/2024 1:14:04 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ions-20240909.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="30.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139912844705968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M\N JK3RUPSNX/2\D*\+#8'J5^PF61K#S>5ZO3XP?KM=*5GN]@UOS_\CF2N5
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ '80I69>*NQS
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M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
M'80I620>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ '80I60=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  =A"E9T5M0
M$N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  =A"E9F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !V$*5FZ 1\_0@0  (,0
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  =A"E9GZ ;\+$"  #B#   #0              @ &&#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !V$*5F7BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d881331d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d881331d8k.htm">d881331d8k.htm</File>
    <File>ions-20240909.xsd</File>
    <File>ions-20240909_lab.xml</File>
    <File>ions-20240909_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d881331d8k.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20240909",
   "dts": {
    "inline": {
     "local": [
      "d881331d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20240909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20240909_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20240909_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-09_to_2024-09-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d881331d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-09_to_2024-09-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d881331d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ionispharma.com//20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-24-215939-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-215939-xbrl.zip
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M L)D?4MI99C=R)21CH<3EZE>0(<Z 8;[N=DL>+GT;8@A_RZ:9A_K60=%I4B
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M<,H68\"Z(2]C+-/07M)PB> 5N#R>!B($"3MRIQ;("!OM.I((T:?KC[C/,$E
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M&U/[QTOTP+P4+2"YY[<=#6/H-HWCV+E@E$HWE?LH2*(< 6 J5W&4?.4S6=&
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M4&*2MS?+^N(3TZGSM5KTQGQ:$ZC9O6IU.ITW.ZMV)L]:_93^+R4\B@M>Z '
MU7A@Y<XEXRI2;GN=[;Y(6=KO%;)FYD:*VNXOOZQ&[*=F>X/8[PJQ/[CTE;F^
M*8BOKWNK04S?$+1RWQ"L&]3/!9[OC5DV8OAY+ =,C=Q@]KO"[ \NB+.-/X7+
ME1B6VVVM+Z<;(']70/XQ\&KNZ:7R]]/)EP(V\,D7UO&&LN;J!KO?%79_<"%L
M)"VFF/YXUNP6L(G3_,53F9RP ?9W!>P? []9<F4*W[//_=7H?6"RX@;;WQ6V
M?W"A_2UN4F?LQ[$P'#M9S8.=41,FG68S;'CLN^*Q'X.5^CS@ S?)*9#KBVZO
MW]]?#>"N[TZM:3RF^DA?1,B_%PA_;ZRQ41/%,@TNH4GV*WY]>:GKS6>%>3>H
M_#Y0^5V ;_6A2E>7>P?IX7?;GT_:C68!I](;"7>"CZAJ<QN)^IS8G3\D:AU)
M=:JI[_  L=W%YX=MU]Z\]F%@<V=_-;VI\>$2)6(N^D("<^[IR"/\=C2*G8G\
MU,*A]$W\1F+ U;$ZZJM ^2E%D-7Y ./^#U56!XL\RHOR)*W59XYMR@"OZ]/D
MIQD&/7G2U4J_\,*QRWWSB!>=L,M.C4.REN7A[O\W2HRE!Q#?*U*H6,7^LI>6
MG&-83/<\6A05I.^<*)*JGI69UMXJVSMB_52+%Y83_X48JE57@:C^XX.H5[ >
MR4R9 WFYME/G[%/S_$I_5@MW%2J5Y3G_#<6<J9D6(-,W-'K9&7J(\JLG76[,
MR95H2+\Y.]H@_5ZDKQ27C<<@?2E[?)-(;V'Q]BBF+YMD#=.)_DK\*WX!JT^"
MLW2YJ"%6\YXY @DK#25>6L[&\D>>D]8$D\?1I*]M,+G!Y I,MO'<<"Q,2 >[
M+L8GMT(\[@@/N<.862 ]@9'P_'@:X&E4\.<&:ANHK8!:<W7E2/SF' ]]?HA_
M^=\(IXW=")(K+?J+IEEVJ-29*D<,=IPJZ*LM2,.$6W;*T@9W&]RM$F-9[0H'
M32]95VC1Y^N9+Z*K=#EA%)N V]L ;A-D68&W[K+BW'7I*$N4U>N[;/OT8_.Z
MOL#CG0@ @N]B<;QII+V#,E>G0V#=Z5CPV$]KT&Q0N4'EJM"?%'W"K/I>&["K
M<.#$N5!,8V^?;7?/N[4%N%P9E>X*K*<KDJA\(<*_!MP:B[2VC:[GM<'J!JN%
M+$4 X^YNE6U?M%O=NCP5D%.)0B>R7!\WP](SM,GQ=3B3I1O0QJ2-H"PR,U.E
M9F,[;H!8 (BG@#2?3C+"LX[REN*WF-I)?M1(8!DX*DNK#JAGVQ^;DG_0O-VM
MK2Y?R[:;Y_TW3)9%4U%,+'NFXOFS)=WTX5!S\0(5'E !*#SZ7'&H\$8 1:1E
MB0T2Y,DH&0[!3D?J"OR-6U,J(R\K82VM.;6:BY^_WI*NI'1%9?*S(_B0S)_P
MS,6NU*+0B"SZ:VS1/OCLO2<563.2*(O4-@O,M$G GCS2H?MEKM9^C6IZ.:F-
MP6?J=1D%72-S"+,&1C!V!4S6G^"Y&H&@6>K^\D>Z%:]]9W8XE,-_Z8)<9WYX
MRT.[?.[[=/YU'^MH+MB@?^[EUT"-TO[II#:XI,\7I(-F<.>.4DZ&:MRN&K?Q
MGCJ]XL9W;_#H;2\A*(!LR%)/P&^1_>'9MQ76QR.K[FE1'84A*V;C40@N'DRK
MMDV,YT(QPN_[X>5<P3)Y@HNJLDU@4G5U$0.Y)P=)A.P9I2<TQ-GAN.KT.GTX
MA)&X@]:QV<I< >C(W/7I=SN7O>9O3;;M46^(OC>EM)KQ=NP/]35UI-FV"%P?
MC19Y59^XN^UXOKI(8TM/3=T&TG/HU5<O<)@U'N */W/C- X]S1VQ:?(Z$4)8
M8SKJQ,&9(%E4K="T0F1*BH5GE].A/X8\6=S)V*PEFJ8WX=&+WI1%B)"TQ0K[
M%>R=2%V-]$DBV>OI.2+JS@"<#^AO]K+E)ZX]?U&J]=GK.O-J[CJA:_8JEBST
MYMJ>\.GLI0"6:NZ:IN?<#3Q+9[XS(,L?"\8 NG?!_*2:G;UZZ[ASO=WBZ_H:
MI9'!FF E8YBR.M(Q8O*H.IRL/"(&]Z!B9SB]AY\10W10$N"7<=>]C_4]@0>D
M\="1E>Y)1@%40('HCNC@,(1#A9WA,7@)'2:3]460!W.?.Y-('Z(=R\]X=0("
MFB1LS,,![KC*_Y:-9T8H"CP4#TL_L[ZPDE">Y7T./T92R?0$G0C9M(A/:H>'
M>Q7\ P\]PR-JH4&JBBQKX@(ZP!4>XBDY"#0\"@AF3=D32^493)J^U5%BEQ#-
M+)[@B<2R']TZG22]L'&*9Q:0OFB-X7+CLKGR:'!HM;1,KC,C*B5C5R07J;2Q
MHXXKD]2/G6C(TQ6QD@AT&NIS].5T,63Y1IH'J<Y\\7%"\ @>CV:%/FX#X'G7
M:E?3!RO%(:M84;N4)Z0IS4,?ZRUGDC\GK')O!2J=3A[+2$=.4X%O%X\>]!&9
M'AYZE9WNH4]MQ\-ET&VX44,VRD#G=8L\!3L; 2TM%<-&H-+Y5<.AK M/>*75
MCM@XF<ASXM/SW$NZ[+\Z$U&@%4ZUBQ/'M=6A;:G.HX\H) .E?9L'>+#A&J"&
M!%+%PJE$;@"2V<9C&W,TO@>.2(?,SW>\I05%-\FJ+Y6L"@/-KYZ#IY!%V49>
MO]TR3:!LUXYXWN*!.F),*9X>'D2OY)K6/[-<./'!J@]E2FQ3'B,IT\\P#_K,
M+U+:NU8M_V(>/(UG)XH_$WFL"CJG-ON7+,+L3E7CT8-:_Y?9NE06 @6GA\*M
M"^XTRO$D OLW !>:?%8\/#"Z5QR#$2ZW$?+T^".Q1]*8BK1: WM%R-]3V[VB
MU"$Q$&E$M*Y(?\?(C_[ U:H+CU0);'4^UKU#*JE3X.B$ B[UV #K./^9.&"P
MJ*-#U'FJ& )P^6UE*=L^]).%K!$4RF7%=;5*=54[]31N=E^9S8U\> :_]]V"
MN?0['R^;UY][[9<^NP3\_X2KHTG&*6PELRE.,HR[]IW\;B*SZ1J[Y&+Q"=G
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M53=PN-[!\Y-FIU='U; QV[]02P,$%     @ '80I67=CXF\Z!@  G4,  !4
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M_M,E_P!02P$"% ,4    "  =A"E9)L9'B=4G  !"\0  #@
M@ $     9#@X,3,S,60X:RYH=&U02P$"% ,4    "  =A"E9R^_\Q?("  #O
M"0  $0              @ $!*   :6]N<RTR,#(T,#DP.2YX<V102P$"% ,4
M    "  =A"E9=V/B;SH&  "=0P  %0              @ $B*P  :6]N<RTR
M,#(T,#DP.5]L86(N>&UL4$L! A0#%     @ '80I65@S;["4!   8"H  !4
M             ( !CS$  &EO;G,M,C R-# Y,#E?<')E+GAM;%!+!08
..!  $  $!  !6-@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d881331d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20240909.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-09_to_2024-09-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2024-09-09</startDate>
            <endDate>2024-09-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="duration_2024-09-09_to_2024-09-09"
      id="Hidden_dei_AmendmentFlag_duration_2024-09-09_to_2024-09-09">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-09_to_2024-09-09"
      id="Hidden_dei_EntityCentralIndexKey_duration_2024-09-09_to_2024-09-09">0000874015</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_0">2024-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-579">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-580">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-581">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-582">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-583">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_2">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_4">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_3">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-588">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-589">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-590">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-591">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-592">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-593">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-09_to_2024-09-09" id="Fact_15">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-595">IONS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-596">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-09_to_2024-09-09" id="ixv-597">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
